



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 18:55  
**Last Report Issued** 12/26/2007 11:05

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 4479B-POS  
**Patient ID** 4479B-POS  
**Chain 1**  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 07003481  
**Received** 12/26/2007

**Lab ID** 07003481-001  
**Matrix** Blood  
**Patient Name** 4479B-POS  
**Patient ID** 4479B-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**4479B Tiagabine, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Tiagabine	5000	ng/mL	4.0	ELEVATED
-----------	------	-------	-----	----------

Synonym(s): Gabitril®

Trough plasma levels of 5 - 70 ng/mL have been reported as the most probable range for seizure control.

Peak plasma concentrations and elimination half-life are affected by fat content in food, time of day and concomitant medications.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.